Tags

Type your tag names separated by a space and hit enter

Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Postgrad Med. 2011 Sep; 123(5):27-38.PM

Abstract

OBJECTIVES

To explore the clinical and health-related quality of life (HRQoL) outcomes in children/adolescents with attention-deficit/hyperactivity disorder (ADHD) who required a therapy switch from immediate-release (IR) methylphenidate (MPH) and were initiated on Osmotic Release Oral System (OROS(®)) MPH.

METHODS

Prospective, noninterventional study including patients (aged 6-18 years) with a confirmed diagnosis of ADHD who transitioned from IR MPH to OROS(®) MPH based on medical needs. Patients were transitioned to OROS(®) MPH and were followed for 12 weeks. Attention-deficit/hyperactivity disorder symptoms, functional outcomes, HRQoL, and tolerability were assessed throughout the study.

RESULTS

598 patients entered the intention-to-treat analysis. The mean OROS(®) MPH starting dose was 29.5 ± 12.0 mg/day, increasing slightly to 33.5 ± 13.2 mg/day at final visit. Compared with baseline, there were significant (all P < 0.0001) symptomatic, functional, and HRQoL improvements after transitioning from IR MPH to OROS(®) MPH as assessed by the Conners' Parent Rating Scale (from 29.0 ± 10.5 to 19.5 ± 11.1), Children's Global Assessment Scale (by 11.0 ± 13.3), and Inventory for Assessing Quality of Life (ILC) LQ0-28 scores (parents' rating from 17.2 ± 3.9 to 19.4 ± 4.0; patients' rating from 18.7 ± 4.0 to 20.5 ± 3.9). Overall, no significant changes in quality of sleep or appetite were observed. More than 70% of parents and physicians rated the effectiveness of OROS(®) MPH as at least "good" and were at least "satisfied" with OROS(®) MPH. The most common treatment-emergent adverse events were insomnia and anorexia. No clinically relevant changes in body weight or vital signs were observed.

CONCLUSIONS

In this naturalistic setting, transitioning from IR MPH to OROS(®) MPH, in patients who showed previously insufficient response and/or poor tolerability, was successful. Patients' and parents' HRQoL as well as burden of disease showed a clinically relevant improvement. OROS(®) MPH was generally safe and well tolerated.

Authors+Show Affiliations

Klinik für Psychiatrie und Psychotherapie, Lübeck, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

21904084

Citation

Kordon, Andreas, et al. "Exploring the Impact of Once-daily OROS® Methylphenidate (MPH) On Symptoms and Quality of Life in Children and Adolescents With ADHD Transitioning From Immediate-release MPH." Postgraduate Medicine, vol. 123, no. 5, 2011, pp. 27-38.
Kordon A, Stollhoff K, Niederkirchner K, et al. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgrad Med. 2011;123(5):27-38.
Kordon, A., Stollhoff, K., Niederkirchner, K., Mattejat, F., Rettig, K., & Schäuble, B. (2011). Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgraduate Medicine, 123(5), 27-38. https://doi.org/10.3810/pgm.2011.09.2457
Kordon A, et al. Exploring the Impact of Once-daily OROS® Methylphenidate (MPH) On Symptoms and Quality of Life in Children and Adolescents With ADHD Transitioning From Immediate-release MPH. Postgrad Med. 2011;123(5):27-38. PubMed PMID: 21904084.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. AU - Kordon,Andreas, AU - Stollhoff,Kirsten, AU - Niederkirchner,Käte, AU - Mattejat,Fritz, AU - Rettig,Klaus, AU - Schäuble,Barbara, PY - 2011/9/10/entrez PY - 2011/9/10/pubmed PY - 2011/11/9/medline SP - 27 EP - 38 JF - Postgraduate medicine JO - Postgrad Med VL - 123 IS - 5 N2 - OBJECTIVES: To explore the clinical and health-related quality of life (HRQoL) outcomes in children/adolescents with attention-deficit/hyperactivity disorder (ADHD) who required a therapy switch from immediate-release (IR) methylphenidate (MPH) and were initiated on Osmotic Release Oral System (OROS(®)) MPH. METHODS: Prospective, noninterventional study including patients (aged 6-18 years) with a confirmed diagnosis of ADHD who transitioned from IR MPH to OROS(®) MPH based on medical needs. Patients were transitioned to OROS(®) MPH and were followed for 12 weeks. Attention-deficit/hyperactivity disorder symptoms, functional outcomes, HRQoL, and tolerability were assessed throughout the study. RESULTS: 598 patients entered the intention-to-treat analysis. The mean OROS(®) MPH starting dose was 29.5 ± 12.0 mg/day, increasing slightly to 33.5 ± 13.2 mg/day at final visit. Compared with baseline, there were significant (all P < 0.0001) symptomatic, functional, and HRQoL improvements after transitioning from IR MPH to OROS(®) MPH as assessed by the Conners' Parent Rating Scale (from 29.0 ± 10.5 to 19.5 ± 11.1), Children's Global Assessment Scale (by 11.0 ± 13.3), and Inventory for Assessing Quality of Life (ILC) LQ0-28 scores (parents' rating from 17.2 ± 3.9 to 19.4 ± 4.0; patients' rating from 18.7 ± 4.0 to 20.5 ± 3.9). Overall, no significant changes in quality of sleep or appetite were observed. More than 70% of parents and physicians rated the effectiveness of OROS(®) MPH as at least "good" and were at least "satisfied" with OROS(®) MPH. The most common treatment-emergent adverse events were insomnia and anorexia. No clinically relevant changes in body weight or vital signs were observed. CONCLUSIONS: In this naturalistic setting, transitioning from IR MPH to OROS(®) MPH, in patients who showed previously insufficient response and/or poor tolerability, was successful. Patients' and parents' HRQoL as well as burden of disease showed a clinically relevant improvement. OROS(®) MPH was generally safe and well tolerated. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/21904084/Exploring_the_impact_of_once_daily_OROS®_methylphenidate__MPH__on_symptoms_and_quality_of_life_in_children_and_adolescents_with_ADHD_transitioning_from_immediate_release_MPH_ L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.2011.09.2457 DB - PRIME DP - Unbound Medicine ER -